Patrick Kelly, MD
Radiation Oncology · Orlando, FLNPI 1043417405
Payments from drug & device makers
What this record shows
8 manufacturers reported payments, led by Biocompatibles, Inc. at 42.2% of the total. Reporting peaked in 2019 at $1,232 and has fallen 94.8% since, to $64 in 2025.
Across 19 payments — averaging $127.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biocompatibles, Inc.$1K
- Siemens Medical Solutions USA, Inc.$603
- Boston Scientific$445
- Varian Medical Systems, Inc.$206
- Viewray Technologies Inc$74
- Elekta, Inc.$33
- plus $43 from 2 others
Across 14 payments — averaging $14,927 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Viewray Technologies Inc$109K
- Varian Medical Systems, Inc.$40K
- Mevion_medical_systems_inc$40K
- Siemens Medical Solutions USA, Inc.$21K
What the payments were for
- Travel & lodging$1,34555%
- Food & beverage$1,08645%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biocompatibles, Inc. | 5 | $1,025 |
| Siemens Medical Solutions USA, Inc. | 1 | $603 |
| Boston Scientific | 4 | $445 |
| Varian Medical Systems, Inc. | 5 | $206 |
| Viewray Technologies Inc | 1 | $74 |
| Elekta, Inc. | 1 | $33 |
| Stryker | 1 | $31 |
| Novartis | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,430 in reported general payments places this provider in the 70th percentile of 465 radiation oncology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Mometasone Furoate | 12 | $198 |
| Dexamethasone | 16 | $100 |
| Omeprazole | 13 | $83 |
| Ondansetron Hcl | 11 | $67 |
Paid to pharmacies, not to this prescriber.
Other radiation oncology in Orlando
- Shravan KandulaOrlando$444K
- Ravi ShridharOrlando$192K
- Akash NandaOrlando$165K
- Imran MohiuddinOrlando$93K
- Charles HodgeOrlando$34K
- Bridget KoontzOrlando$26K
- Justin RineerOrlando$11K
- Matthew BiagioliOrlando$10K
- Shiv DesaiOrlando$8K
- Nina JohnsonOrlando$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.